Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEO-CM02
- Development stage
- Preclinical
- Lead developer
- GeoVax Labs
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GEO-CM02 is a pan-coronavirus vaccine candidate developed by GeoVax Labs using its proprietary Modified Vaccinia Ankara (MVA) vector platform. The vaccine is designed to express multiple antigens that self-assemble into virus-like particles (VLPs) in the vaccinated individual, aiming to induce broad and durable immune responses against SARS-CoV-2 and other coronaviruses. In January 2021, the program received a Phase 1 Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) to support its preclinical development. Unlike first-generation vaccines that focus solely on the spike protein, GEO-CM02 is engineered to provide a more comprehensive immune profile to address emerging variants and potentially other coronavirus species.
- Other names
- GV-MVA-VLP vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on GEO-CM02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEO-CM02.